How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

550 results for

Famciclovir

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

481. Improving the care of patients with genital herpes (PubMed)

Valacyclovir QIC03ANI02 Famciclovir X4HES1O11F Acyclovir AIM IM BMJ. 2001 Feb 17;322(7283):434 11179175 2-Aminopurine analogs & derivatives therapeutic use Acyclovir analogs & derivatives therapeutic use Adult Antiviral Agents therapeutic use Cesarean Section Drug Administration Schedule Famciclovir Female Herpes Genitalis diagnosis drug therapy epidemiology Humans Immunocompromised Host Infant, Newborn Male Patient Education as Topic Pemphigoid Gestationis drug therapy prevention & control Pregnancy

Full Text available with Trip Pro

2000 BMJ : British Medical Journal

482. Cross-Resistance Testing of Antihepadnaviral Compounds Using Novel Recombinant Baculoviruses Which Encode Drug-Resistant Strains of Hepatitis B Virus (PubMed)

-resistance profiles of drug-resistant HBV strains are described here. For these studies, novel recombinant HBV baculoviruses which encoded the L526M, M550I, and L526M M550V drug resistance mutations were generated and used to examine the effects of these substitutions on viral sensitivity to lamivudine, penciclovir (the active form of famciclovir), and adefovir, three compounds of clinical importance. The following observations were made: (i) the L526M mutation confers resistance to penciclovir

Full Text available with Trip Pro

2001 Antimicrobial Agents and Chemotherapy

483. In Vitro Susceptibilities of Wild-Type or Drug-Resistant Hepatitis B Virus to (−)-β-d-2,6-Diaminopurine Dioxolane and 2′-Fluoro-5-Methyl-β-l-Arabinofuranosyluracil (PubMed)

In Vitro Susceptibilities of Wild-Type or Drug-Resistant Hepatitis B Virus to (−)-β-d-2,6-Diaminopurine Dioxolane and 2′-Fluoro-5-Methyl-β-l-Arabinofuranosyluracil Prolonged treatment of chronic hepatitis B virus (HBV) infection with lamivudine ([-]-beta-L-2',3'-dideoxy-3' thiacytidine) or famciclovir may select for viral mutants that are drug resistant due to point mutations in the polymerase gene. Determining whether such HBV mutants are sensitive to new antiviral agents is therefore (...) important. We used a transient transfection system to compare the sensitivities of wild-type HBV and four lamivudine- and/or famciclovir-resistant HBV mutants to adefovir [9-(2-phosphonyl-methoxyethyl)-adenine; PMEA] and the nucleoside analogues (-)-beta-D-2, 6-diaminopurine dioxolane (DAPD) and 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil (L-FMAU). The drug-resistant mutants contained amino acid substitutions in the polymerase protein. We found that the M550I and M550V plus L526M substitutions

Full Text available with Trip Pro

2001 Antimicrobial Agents and Chemotherapy

484. Famvir effective in suppressing recurrent genital herpes. (PubMed)

Famvir effective in suppressing recurrent genital herpes. 11362073 1999 04 01 2018 12 01 1087-2914 12 12 1998 Dec AIDS patient care and STDs AIDS Patient Care STDS Famvir effective in suppressing recurrent genital herpes. 944 eng Clinical Trial Multicenter Study News Randomized Controlled Trial United States AIDS Patient Care STDS 9607225 1087-2914 0 Antiviral Agents 452-06-2 2-Aminopurine QIC03ANI02 Famciclovir X 2-Aminopurine analogs & derivatives therapeutic use Antiviral Agents therapeutic (...) use Double-Blind Method Famciclovir Female Herpes Simplex drug therapy prevention & control Humans Male Recurrence 2001 5 22 10 0 2001 5 22 10 1 2001 5 22 10 0 ppublish 11362073

1999 AIDS patient care and STDs Controlled trial quality: uncertain

485. Percutaneous electrical nerve stimulation: an alternative to antiviral drugs for acute herpes zoster. (PubMed)

Ghoname E S ES Hamza M A MA Gajraj N M NM Taylor S M SM eng Clinical Trial Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't United States Anesth Analg 1310650 0003-2999 0 Antiviral Agents 452-06-2 2-Aminopurine QIC03ANI02 Famciclovir AIM IM Anesth Analg. 1999 Dec;89(6):1585-6 10589658 2-Aminopurine analogs & derivatives therapeutic use Acute Disease Adult Antiviral Agents therapeutic use Famciclovir Female Herpes Zoster therapy Humans Male Middle Aged Pain Management Pain

1998 Anesthesia and Analgesia Controlled trial quality: uncertain

486. [Expensive long-term care with virustatic drugs frequently reduces herpes genitalis episodes]. (PubMed)

-Episoden. Switzerland Praxis (Bern 1994) 101468093 1661-8157 0 Antiviral Agents 452-06-2 2-Aminopurine QIC03ANI02 Famciclovir IM 2-Aminopurine administration & dosage analogs & derivatives economics Adult Antiviral Agents administration & dosage economics Cost-Benefit Analysis Double-Blind Method Drug Costs Famciclovir Female Herpes Genitalis drug therapy economics Humans Long-Term Care economics Male Recurrence 1999 7 27 1999 7 27 0 1 1999 7 27 0 0 ppublish 10420805

1999 Praxis Controlled trial quality: uncertain

487. Economic evaluation of antiviral therapy for the treatment of herpes zoster in immunocompetent adults. (PubMed)

of the cost-effectiveness of the 2 most commonly used oral antiviral treatments that have proven efficacy in patients with shingles: famciclovir and aciclovir (acyclovir). It shows that the clinical advantages of famciclovir over aciclovir are accompanied by potential economic advantages in the form of savings in direct costs to the UK National Health Service of between 2.04 pounds and 16.85 pounds per patient treated. Future economic research to validate the benefits of antiviral treatment should focus

1997 PharmacoEconomics Controlled trial quality: uncertain

488. Lamivudine as first- and second-line treatment of hepatitis B infection after liver transplantation. (PubMed)

Lamivudine as first- and second-line treatment of hepatitis B infection after liver transplantation. Lamivudine and famciclovir have expanded therapeutical options for HBV infection after liver transplantation. First studies confirm good antiviral effects of both, but at present the major problem seems to be a rapid resistance formation in immunosuppressed patients. Thirty-four adult patients with HBV recurrence despite passive immunoprophylaxis and seven with de novo infection after orthotopic (...) liver transplantation (OLT) were treated with 100-150 mg lamivudine daily. Patients were either treated directly after infection (n = 14) or after breakthrough of viral replication during an initial famciclovir therapy (n = 27). All patients except two responded to treatment with a reduction of serum HBV-DNA of over 50%. Thirty-one patients (76%) turned HBV-DNA-negative during lamivudine therapy. Viral breakthrough was observed in 14 of these patients after 4-13 months of treatment. A total of 17

2000 Transplant international : official journal of the European Society for Organ Transplantation Controlled trial quality: uncertain

489. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. (PubMed)

HBeAg seroconversion. There was no increase in the rate of development of YMDD variants or L528M mutation in patients receiving lamivudine 25 mg daily or famciclovir 500 mg 3 times a day before being given lamivudine 100 mg daily.

Full Text available with Trip Pro

2001 Hepatology Controlled trial quality: uncertain

490. Economic evaluation of famciclovir in reducing the duration of postherpetic neuralgia

Economic evaluation of famciclovir in reducing the duration of postherpetic neuralgia Economic evaluation of famciclovir in reducing the duration of postherpetic neuralgia Economic evaluation of famciclovir in reducing the duration of postherpetic neuralgia Huse D M, Schainbaum S, Kirsch A J, Tyring S Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results (...) and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Famciclovir therapy for reducing the duration of post-herpetic neuralgia (PHN). Type of intervention Secondary prevention. Economic study type Cost-effectiveness analysis. Study population Immunocompetent adults with uncomplicated herpes zoster, diagnosed within 72 hours of onset of rash. Setting Primary care centres in the US, Canada and Australia. Dates to which data relate

1997 NHS Economic Evaluation Database.

491. If a rugby player is getting recurrent attacks of scrumpox currently treated with Famciclovir 750mg daily for 1 week - is there evidence for the benefits of more longterm prophylactic antivirals?

If a rugby player is getting recurrent attacks of scrumpox currently treated with Famciclovir 750mg daily for 1 week - is there evidence for the benefits of more longterm prophylactic antivirals? If a rugby player is getting recurrent attacks of scrumpox currently treated with Famciclovir 750mg daily for 1 week - is there evidence for the benefits of more longterm prophylactic antivirals? - Trip Database or use your Google+ account Liberating the literature ALL of these words: Title only (...) If a rugby player is getting recurrent attacks of scrumpox currently treated with Famciclovir 750mg daily for 1 week - is there evidence for the benefits of more longterm prophylactic antivirals? We searched the NLH Specialist Library for Skin Conditions and the TRIP and Medline databases but found no guidance on the management of recurrent scrum pox/herpes simplex of the skin. The BNF offers the following general prescribing information for famciclovir: “ Indications: treatment of herpes zoster, acute

2006 TRIP Answers

492. Is there any evidence for the use of famciclovir in cutaneous H Simplex infections ie H Labialis?

Is there any evidence for the use of famciclovir in cutaneous H Simplex infections ie H Labialis? Is there any evidence for the use of famciclovir in cutaneous H Simplex infections ie H Labialis? - Trip Database or use your Google+ account Liberating the literature ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe (...) across other content types including images, videos, patient information leaflets, educational courses and news. For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com Is there any evidence for the use of famciclovir in cutaneous H Simplex infections ie H Labialis? We found little evidence to support the use of famciclovir in the prevention or treatment of herpes

2006 TRIP Answers

493. Efficacy and Safety of Famciclovir 1-day Treatment Compared to 3-day Treatment With Valacyclovir in Adults With Recurrent Genital Herpes

Efficacy and Safety of Famciclovir 1-day Treatment Compared to 3-day Treatment With Valacyclovir in Adults With Recurrent Genital Herpes Efficacy and Safety of Famciclovir 1-day Treatment Compared to 3-day Treatment With Valacyclovir in Adults With Recurrent Genital Herpes - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study (...) Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Efficacy and Safety of Famciclovir 1-day Treatment Compared to 3-day Treatment With Valacyclovir in Adults With Recurrent Genital Herpes The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier

2006 Clinical Trials

494. RELIEF: Randomized Episodic Versus Long-Term Suppression Experience With Famciclovir

RELIEF: Randomized Episodic Versus Long-Term Suppression Experience With Famciclovir RELIEF: Randomized Episodic Versus Long-Term Suppression Experience With Famciclovir - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before (...) adding more. RELIEF: Randomized Episodic Versus Long-Term Suppression Experience With Famciclovir The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00219310 Recruitment Status : Completed First Posted : September 22, 2005 Last Update Posted : April 27, 2012 Sponsor: Novartis Information provided

2005 Clinical Trials

495. A Study to Evaluate the Safety and Efficacy of Single Day or Single Dose Famciclovir for the Treatment of Recurrent Herpes Labialis

A Study to Evaluate the Safety and Efficacy of Single Day or Single Dose Famciclovir for the Treatment of Recurrent Herpes Labialis A Study to Evaluate the Safety and Efficacy of Single Day or Single Dose Famciclovir for the Treatment of Recurrent Herpes Labialis - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have (...) reached the maximum number of saved studies (100). Please remove one or more studies before adding more. A Study to Evaluate the Safety and Efficacy of Single Day or Single Dose Famciclovir for the Treatment of Recurrent Herpes Labialis The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00248144

2005 Clinical Trials

496. Pharmacokinetics, Acceptability and Safety of Famciclovir in Infants (1 Month to Less Than 12 Months) With Herpes Simplex Infection

Pharmacokinetics, Acceptability and Safety of Famciclovir in Infants (1 Month to Less Than 12 Months) With Herpes Simplex Infection Pharmacokinetics, Acceptability and Safety of Famciclovir in Infants (1 Month to Less Than 12 Months) With Herpes Simplex Infection - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have (...) reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Pharmacokinetics, Acceptability and Safety of Famciclovir in Infants (1 Month to Less Than 12 Months) With Herpes Simplex Infection The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00448227

2007 Clinical Trials

497. A Study to Evaluate the Effect of Famciclovir in Reducing Herpes Virus Shedding

A Study to Evaluate the Effect of Famciclovir in Reducing Herpes Virus Shedding A Study to Evaluate the Effect of Famciclovir in Reducing Herpes Virus Shedding - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more (...) . A Study to Evaluate the Effect of Famciclovir in Reducing Herpes Virus Shedding The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00129818 Recruitment Status : Completed First Posted : August 12, 2005 Last Update Posted : April 27, 2012 Sponsor: Novartis Information provided by: Novartis Study Details

2005 Clinical Trials

498. Famciclovir Oral Pediatric Formulation in Children 1-12 Years of Age With Varicella Zoster Infection

Famciclovir Oral Pediatric Formulation in Children 1-12 Years of Age With Varicella Zoster Infection Famciclovir Oral Pediatric Formulation in Children 1-12 Years of Age With Varicella Zoster Infection - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please (...) remove one or more studies before adding more. Famciclovir Oral Pediatric Formulation in Children 1-12 Years of Age With Varicella Zoster Infection The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00098046 Recruitment Status : Completed First Posted : December 3, 2004 Last Update Posted : September 26

2004 Clinical Trials

499. Famciclovir Pediatric Formulation in Children 1 to 12 Years of Age With Herpes Simplex Infection

Famciclovir Pediatric Formulation in Children 1 to 12 Years of Age With Herpes Simplex Infection Famciclovir Pediatric Formulation in Children 1 to 12 Years of Age With Herpes Simplex Infection - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one (...) or more studies before adding more. Famciclovir Pediatric Formulation in Children 1 to 12 Years of Age With Herpes Simplex Infection The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00098059 Recruitment Status : Completed First Posted : December 3, 2004 Results First Posted : May 6, 2009 Last Update

2004 Clinical Trials

500. Efficacy and Safety of Oral Famciclovir in Patients With Active Recurrent Genital Herpes

Efficacy and Safety of Oral Famciclovir in Patients With Active Recurrent Genital Herpes Efficacy and Safety of Oral Famciclovir in Patients With Active Recurrent Genital Herpes - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies (...) before adding more. Efficacy and Safety of Oral Famciclovir in Patients With Active Recurrent Genital Herpes The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00171990 Recruitment Status : Completed First Posted : September 15, 2005 Last Update Posted : August 15, 2013 Sponsor: Novartis Information

2005 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>